AIM
VRTX icon

Acrospire Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Acrospire Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-600
Closed -$77K – 1393
2017
Q2 		$77K Sell
600
-200
-25% -$24.1K 0.07% 440
2017
Q1 		$87K Sell
800
-2,000
-71% -$176K 0.07% 428
2016
Q4 		$206K Buy
2,800
+2,000
+250% +$163K 0.08% 340
2016
Q3 		$70K Buy
800
+300
+60% +$28.4K 0.05% 822
2016
Q2 		$43K Buy
500
+100
+25% +$8.64K 0.03% 1173
2016
Q1 		$32K Buy
+400
New +$36.2K 0.02% 1280

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Acrospire Investment Management's VRTX Position: Q3 2017 in Review

Acrospire Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2017, closing a stake of 600 shares — an estimated $77K sold.

Acrospire Investment Management first reported a position in VRTX in Q1 2016 and held it in 6 quarters. The position peaked at $206K in Q4 2016. 611 funds tracked by Wall St. Rank hold VRTX as of Q3 2017.

  • Acrospire Investment Management reported no remaining Vertex Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 600 Vertex Pharmaceuticals shares in Q3 2017, an estimated $77K.
  • Acrospire Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Vertex Pharmaceuticals position peaked at $206K in Q4 2016.
  • 611 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.